Biocracked
Longevity Metabolism Peptides Research Supplements Trending: supplements clinical trial longevity nad+ nootropics
Approach: the human outcome. Palette: bold color field. Close-up of an older person's weathered hands, shot from slightly above and to the side, wrapped around an electric green enamel mug against a flat saturated mustard-yellow wall. The fingers show a faint tremor. The mug and knuckles are sharp, while the fingertips and the surface of the tea have a soft motion blur. The face is out of frame, with only a grey wool cardigan cuff visible. Low-angle, soft window light from the left casts a gentle warm shadow on the wall and picks out the skin's creases, veins and age spots. The mood is quiet and sober, with a hint of disappointment. The image is photorealistic and uncluttered, with generous empty yellow space on the right, no text and no pills.
Research

Uji Coba Suplemen NAD+ Paling Gedhé Kanggo Parkinson Gagal

Lyra Voss · · 4 min read

Uji Coba Suplemen NAD+ Paling Gedhé Kanggo Parkinson Gagal

Nikotinamid ribosida (NR), sing dipasarake kanthi jeneng Niagen lan Tru Niagen, iku salah siji suplemen awet urip paling populer ing pasar. Saiki NR wis ngadhepi uji paling gedhé ing penyakit saraf, lan asilé ora nguntungaké. Ing uji fase 3 NOPARK sing diterbitake ing JAMA Oktober 2026, pasien Parkinson awale sing njupuk NR nuduhaké asil sing rada luwih ala tinimbang sing nampa plasebo. Pengaruhe cilik, nanging arahé mbantah pangarep‑arep lapangan.

Apa sing ditindhakaké uji coba iki

NOPARK iku uji coba fase 3 sing acak, double‑blind, lan dikontrol plasebo, dilakokaké ing 11 pusat ing Norway.

  • Sapa: Wong diwasa umur 35 taun utawa luwih, diagnosa Parkinson ing wektu rong taun kepungkur, Hoehn lan Yahr stage ngisor 3, scintigraphy transporter dopamin abnormal sing nuduhaké ilangé neuron dopaminergik nigrostriatal, lan pangobatan dopaminergik sing wis stabil.
  • Jumlah sampel: 537 wong disaring lan 410 diacak antarane Mei 2020 lan Juni 2024. Saka kana, 393 kalebu ing analisis utama.
  • Karakteristik: Umur rata‑rata 65,6 taun (SD 9,4), lan 34 % wanita.
  • Intervensi: NR oral 500 mg kaping loro saben dina (total 1 000 mg / hari) utawa plasebo sing cocok, suwene 52 minggu.
  • Outcome utama: Owah‑owahan total MDS‑UPDRS (bagian I–III) saka wiwitan nganti minggu 52. Skala iki mundhak saka 0 nganti 236, lan angka luwih dhuwur nuduhaké penyakit sing luwih parah.

Pangukuran pungkasan rampung ing Juni 2025. Uji coba iki kacathet minangka NCT03568968.

Angka‑angka pokok

Ing minggu 52, total skor MDS‑UPDRS mundhak 2,45 poin (95 % CI 0,80–4,10) ing kelompok NR. Ing kelompok plasebo mudhun 0,27 poin (95 % CI ‑1,95 nganti 1,40).

Beda rata‑rata sing wis disetel yaiku 2,72 poin (95 % CI 0,47–4,98; P = .02), milih plasebo.

Beban gejala non‑motor uga nuduhaké pola sing padha. Ing Non‑Motor Symptoms Scale (kisaran 0–360), NR disambungaké karo skor sing luwih ala, kanthi beda rata‑rata sing disetel 4,22 poin (95 % CI 1,07–7,37; P = .009).

Kenapa "luwih ala" butuh konteks

Iki dudu crita pasien sing ngalami kecelakaan parah. Peneliti nggunakaké ambang klinis sing wis dipublikasikaké kanggo owah‑owahan sing penting ing MDS‑UPDRS: 6,7 poin kanggo perbaikan lan 5,2 poin kanggo kemunduran. Jarak 2,72 poin iku signifikan sacara statistik, nanging adoh saka ambang kemunduran. Malah pucuk ndhuwur interval kapercayané (4,98) isih kurang saka 5,2.

Patang saka lima outcome sekunder utama sing wis ditemtokaké sadurungé ora nuduhaké béda signifikan. Iki kalebu bagean I, II, lan III MDS‑UPDRS lan temuan pencitraan transporter dopamin. Sing siji beda yaiku skor non‑motor.

Interpretasi paling sah yaiku NR ora menehi manfaat lan malah kèwané karo skor sing rada luwih ala. Penulis nyimpulaké yèn NR ora ningkataké asil klinis lan malah luwih ala tinimbang plasebo.

Kejutan babagan keamanan

Siji temuan nglawan narasi "NR luwih ala". Kejadian adverse serius kedadeyan ing 17 saka 205 peserta (8,3 %) sing nampa NR lan 29 saka 205 (14,1 %) sing nampa plasebo ing populasi keamanan. Dadi NR ora ana hubungane karo luwih akeh adverse serius; malah luwih sithik. Studi iki ora nerangaké sebab bedane, lan ora kena dijupuk minangka bukti yèn NR nglindhungi saka apa wae.

Kenapa asil iki penting

Pangarep‑arep babagan NR ing Parkinson asalé saka riset praklinis lan studi cilik awale, kalebu karya NADPARK sing padha saka grup Norway iki. Studi‑studi mau nuduhaké yèn NR bisa nambah kadar NAD+ lan mengaruhi metabolisme otak. Nanging, studi‑studi kasebut cilik lan ora dirancang kanggo mbuktekaké mupangat klinis, déné NOPARK dadi tes konfirmasi.

Kredibilitas uga penting dicathet. Sawijining peneliti nduwèni paten NR kanggo Parkinson, lisensi marang Niagen Bioscience (sadurungé ChromaDex), miturut pengungkapan uji coba sing diringkes ing sumber. Peneliti sing duwé kepentingan finansial malah nglaporaké asil négatif, sing nambah bobot asil kasebut. Desainé uga kuwat: double‑blind, kontrol plasebo, diagnosa sing dikonfirmasi kanthi imaging, lan endpoint primer sing wis ditemtokaké sadurungé.

Apa artiné iki kanggo sampeyan

  • Aja nambani dhéwé nganggo NR. Uji coba paling gedhé nemokaké ora ana mupangat lan sinyal cilik ngarahaké marang asil sing luwih ala kanthi dosis 1 000 mg / hari sajrone setaun.
  • Yèn sampeyan wis njupuk NR, rembugan dhisik karo neurologmu sadurungé nggawe keputusan. Aja langsung mandheg utawa ngowahi obat sing wis diwènèhi dokter.
  • Suplemen ora nggantèkaké terapi dopaminergik utawa perawatan standar.

Yèn sampeyan njupuk NR utawa NMN kanggo awet urip umum:

  • Uji coba iki ditujokaké kanggo wong sing nduwèni Parkinson awal, dudu wong sehat. Mulane ora nuduhaké yèn NR mbebayani wong sehat.
  • Iki nglemahaké klaim "naikaké NAD+ lan nglindhungi otak" sing sakabèhé. Yèn NR ora bisa mbantu ing penyakit sing NAD+ dadi target utama, klaim perlindungan saraf ing wong sehat dadi luwih tipis didhukung.
  • NMN ora diuji ing kéné, dadi asil iki ora bisa langsung dipasangaké marang NMN. Rasional biologisé padha, lan skeptisisme sing padha tetep wajar.
  • Dosis lan wektu: uji coba nggunakake 500 mg kaping loro saben dina suwene 52 minggu. Akeh produk komersial migunakaké dosis luwih sithik, mula uji iki ora langsung cocog karo panggunaan suplemen biasané. Ora ana dhasar kanggo nyaranaké dosis utawa jadwal tartamtu.

Sapa sing pantes mikirake NR: sapa wae sing nduwèni Parkinson utawa nduwèni riwayat kulawarga sing kuat lan mikir NR minangka langkah pencegahan utawa modifikasi penyakit, lan sapa wae sing tuku NR awit tujuan perlindungan otak.

Sapa sing isih bisa mikir: wong‑wong sing njupuk NR amarga alesan liya, sing kudu nganggep bukti iki durung pasti, ora cukup kanggo njupuk keputusan. Rembug karo dokter, utamané yèn sampeyan nduwèni penyakit kronis utawa njupuk obat liya.

Ringkesan

NOPARK minangka conto arang banget ing ngendi suplemen populer diuji skala gedhé ing penyakit sing data awalé ndhukung, lan asilé ora nyukupi. Pengaruhe modest lan ngisor ambang klinis, adverse serius luwih sithik ing grup NR, lan studi iki khusus kanggo Parkinson awal. Nanging, minangka terapi sing ngowahi penyakit, NR ora ngasilaké manfaat sing dikarepake.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

Share XFacebookLinkedInRedditWhatsApp
LV

Written by

Lyra Voss

Lyra Voss writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: Conceptual metaphor, palette D (bold color field). A single halved blood orange and a single halved yellow kiwi-style golden kiwi sit side by side on a saturated magenta seamless backdrop, shot from a low three-quarter angle with shallow depth of field. Between them, a thin, slightly cracked glass pane stands upright, partly dividing the two fruits to suggest "association, not cause." Glistening juice vesicles in the orange flesh catch crisp, directional studio light from the upper left, throwing a sharp, short shadow across the glossy magenta surface. A tiny electric green sprig of a fresh leaf rests at the base of the glass as the only green accent. Colors are juicy, vivid and contrasting: magenta, orange, gold. Mood is curious, clean and quietly skeptical, with a food-as-evidence feel. Photorealistic, tactile textures, no text or labels.
research

Vitamin C lan E Digandhengake karo Penurunan Risiko Alzheimer nganti 18 %, Nanging Ana Syarat

BY NOVA CHEN ·

Ing Rotterdam Study sing nglibatake 5.395 wong tuwa, konsumsi vitamin C lan vitamin E saka panganan masing‑masing digandhengake karo penurunan kira‑kira 18 % risiko Alzheimer saben standar deviasi. Pola iki paling cetha ing perokok, nanging beta‑karoten lan flavonoid uga dadi sorotan. Nanging iki mung studi observasional babagan pola mangan, dudu uji coba pil, mula sing diduweni mung hubungan, ora bukti sebab‑akibat. Sawetara angka kanggo perokok malah duwe interval kapercayan sing nyabrang 1,0. Ing ngisor iki apa sing tenan dituduhake data, panganan sumber nutrisi mau, lan piye posisi suplemen.
Approach: macro science, a lithium-themed image built around the actual metal and tissue. Palette: bold color field in saturated teal. Extreme close-up photograph of a single freshly cut piece of silvery lithium metal, its surface partly tarnishing to grey and matte black at the edges, resting on a thin slice of translucent brain tissue on a glass microscope slide. The slice shows fine pink-grey folds and a few dark clumped plaque-like specks. The backdrop is a smooth saturated teal field, with the slide placed diagonally. Shallow depth of field keeps the metal edge razor sharp while the tissue softens toward the corners. Lighting is a crisp, slightly warm side light from the left, with a small specular highlight on the metal and a soft shadow on the teal. A tiny electric green reflection glints in the glass edge. The mood is quiet, investigative and precise. Shot from a low 30-degree angle, with no text or labels.
research

Mineral Jejak sing Ilang saka Otak Sadurunge Alzheimer

BY DR. SYNAPSE ·

Studi penting saka *Nature* sing ditindakake ing Harvard nemokake yèn litium mung logam sing sacara signifikan suda ing otak wong‑wong sing nduwèni gangguan kognitif ringan. Ing tikus, ngurangi litium nganti kira‑kira separo nyebabaké akumulasi amiloid, patologi tau, peradangan, lan kelangan memori, déné litium orotat dosis cilik bisa nyegahé. Senyawa iki katon bisa ngindhari plak amiloid sing nyekel garam litium liya. Nanging asil suplemen iki mung saka tikus, durung ana uji klinis manungsa, lan litium nduwèni risiko nyata kanggo ginjal, tiroid, lan interaksi obat. Kéné apa sing dituduhaké déning studi, apa sing ora, lan apa sing kudu dipantau sabanjuré.
A luminous, editorial-style composition capturing the intersection of botanical luxury and phototherapy wellness. In the foreground, smooth, radiant skin—perhaps a serene close-up of a décolletage or relaxed hands—glows with dewy health, illuminated by a warm 670-nanometer crimson-amber light that creates a soft, sunset-like flare across the frame. Beside it, a hand-blown glass vessel overflows with vivid emerald-green tea, steam rising in ethereal spirals that catch the red light, turning golden at the edges. Fresh, dew-kissed green tea leaves and organic cotton pads soaked in amber liquid rest on a textured stone or raw silk surface, their surfaces glistening with microscopic water droplets. The background features soft-focus green tea branches and warm terracotta ceramics, all bathed in that therapeutic ruby-gold luminosity that suggests cellular rejuvenation. The lighting balances natural daylight with the distinctive deep red glow, creating a rich palette of jade, amber, and crimson. Shallow depth of field, high-end skincare editorial aesthetic, organic textures, and an atmosphere of serene, scientific luxury without any technological harshness.
research

Teh Ijo lan Cahya Abang: Terobosan Sinergi Kanggo Ngilangaké Kerut lan Mbalesaké Umur Kulit

BY DR. SYNAPSE ·

Studi revolusioner taun 2009 negesaké yèn kombinasi polifenol saka teh ijo karo cahya abang 670 nm bisa nganyarke kulit kanthi dramatis, nyuda kerut lan mulihaké apa sing diarani “complessi juvenile”. Carané prasaja: pad kapas rendhem teh ijo 20 menit sadurunge paparan cahya, sing nyawiji anti‑oksidan lan stimulasi energi seluler dadi siji solusi anti‑aging non‑invasif.
A cutting-edge medical laboratory scene showing microscopic nanoparticles floating in a luminous blue-green solution within a glass beaker. The spherical nanoparticles glow with a soft golden light, each decorated with tiny molecular structures representing hyaluronic acid chains. In the background, a cross-sectional view of intestinal tissue is visible on a high-tech monitor, with inflamed areas highlighted in red and healthy tissue in pink. Scientific equipment including pipettes, microscopes, and digital displays surround the workspace. Floating holographic molecular diagrams show peptide structures and delivery pathways. The overall lighting is clean and clinical with blue and white tones, emphasizing the precision and innovation of the breakthrough technology. Glass surfaces reflect the nanoparticles' golden glow, creating a sense of advanced biotechnology and medical progress.
research

Sistem Pangiriman Nanopartikel Revolusioner Ngowahi Terapi Peptida Kanggo Penyakit Usus Radang

BY DR. SYNAPSE ·

Para peneliti wis ngembangaké sistem pangiriman obat sing revolusioner nggunakake nanopartikel sing difungsionalaké karo asam hialuronat kanggo ngirim peptida terapeutik langsung menyang jaringan usus sing radang. Teknologi iki ngatasi tantangan utama ing terapi peptida kanthi nambah stabilitas, target lan bioavailabilitas. Asile nuduhaké potensi sing janjeni kanggo ngobati kolitis ulseratif kanthi ngurangi efek samping liwat pangiriman sing tepat sasaran. Pendekatan iki menehi cara anyar sing luwih spesifik lan aman kanggo pasien.

This page is available in

English العربيةবাংলাČeštinaDeutschEspañolفارسیFrançaisHausaहिन्दीHrvatskiBahasa IndonesiaItaliano日本語Basa Jawa한국어NederlandsਪੰਜਾਬੀPolskiPortuguêsRomânăРусскийSrpskiTürkçeУкраїнськаTiếng Việt中文